Current Biologics Development Projects

This is a preview of the Data Table. Only the first three rows are displayed.
Title Disorder Modality PI/Lead Investigator Institution
Development of anti-LTBP4 as a biologic to treat Neuromuscular Diseases Duchenne Muscular Dystrophy Monoclonal antibody Alexis Demonbreun Northwestern University at Chicago
Preclinical and Early Clinical Development of a Novel Drug for On-Demand Voiding Spinal cord injury Peptide Edward Burgard Dignify Therapeutics, LLC
IND Enabling Non-Clinical Development of E1v1.11, a Morpholino Anti-Sense Oligonucleotide for the treatment of Spinal Muscular Atrophy Spinal Muscular Atrophy Antisense oligonucleotide Steven O'Connor Shift Pharmaceuticals, LLC
Development of Utrophin Site Blocking Oligos (SBOs) to treat Duchenne Muscular Dystrophy (DMD) Duchenne Muscular Dystrophy Site blocking oligonuclotide Tejvir S. Khurana University of Pennsylvania
Development of AAV-AIBP for neuroprotecction in glaucoma Glaucoma AAV-encoding protein Wonkyu Ju University of California- San Diego


BPN-Biologics Staff

Program Director
Dr. Chris Boshoff

Health Program Specialists
Ms. Shruthi Thomas

Operations Coordinator
Ms. Natasha Davis